Patients with ulcerative colitis in remission were randomly allocated to treatment with sulphasalazine (2 g/day) or oral sodium cromoglycate (160 mg/day or 2 g/day), and the relapse rates in these treatment groups were compared during continued treatment for one year. The percentage cumulative relapse rate after 12 months' treatment was 30% in the 33 patients treated with sulphasalazine compared with 71% in the 25 treated with high dose sodium cromoglycate, a highly significant difference (P less than 0.01). Patients allocated low dose sodium cromoglycate were only treated for a maximum of six months, and the relapse rate in these 12 patients was similar to that in patients on the high dose. These results suggest that oral sodium cromoglycate is considerably less effective than sulphasalazine in maintaining remission, and by analogy with results in other trials may be no more effective than placebo tablets.
展开▼
机译：溃疡性结肠炎缓解的患者被随机分配接受柳氮磺胺吡啶（2 g /天）或口服色甘酸钠（160 mg /天或2 g /天）治疗，并比较在连续治疗期间这些治疗组中1个的复发率年。柳氮磺吡啶治疗33例患者，治疗12个月后的累积复发百分率是30％，而高剂量色甘酸钠酸钠治疗的25例中71％，差异有统计学意义（P小于0.01）。分配低剂量色甘酸钠的患者最多只能接受六个月的治疗，这12例患者的复发率与高剂量的患者相似。这些结果表明，口服糖基葡萄糖酸钠在维持缓解方面远不如柳氮磺胺吡啶有效，并且与其他试验的结果类似，它可能没有安慰剂片剂有效。
展开▼
